Skip to main content

Advertisement

Table 1 Baseline characteristics (mean ± SD)

From: Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study

Sex male/female (n) 10/3
Age (year) 64 ± 6
Diabetes duration (year) 8 ± 5
Diabetic values at OGTT yes/no (n) 12/1
Lipid lowering drug (= statin) yes/no (n) 8/5
Drugs per day 4.3 ± 2.3
Anti-hypertensive drugs per day 1.5 ± 1.5
   Beta-blocker yes/no (n) 4/9
   Thiazide yes/no (n) 4/9
   ACE-inhibitor yes/no (n) 5/8
   Angiotensin-II receptor blocker yes/no (n) 4/9
   Calcium channel blocker yes/no (n) 3/10
Anti-diabetic drugs per day 1.2 ± 0.9
   Metformin yes/no (n) 9/4
   Sulfonylurea yes/no (n) 3/10
   Thiazolidinedione yes/no (n) 3/10
Metformin per day (mg) 1031 ± 864
HbA1C (%, Mono-S) 6.6 ± 0.6
Cholesterol (mmol/l) 4.4 ± 1.1
LDL (mmol/l) 2.9 ± 0.9
HDL (mmol/l) 1.28 ± 0.22
TG (mmol/l) 1.5 ± 0.7
CRP (mg/l) 2.4 ± 1.8
SBP (mmHg) 150 ± 21
DBP (mmHg) 83 ± 10
Height (cm) 171 ± 5
Weight (kg) 87 ± 17
BMI (kg/m2) 30 ± 7
Waist (cm) 103 ± 14
fP-glucose (mmol/l) 7.8 ± 1.2
fP-insulin (pmol/l) 98 ± 44
AUC glucose0–120 (mmol/l·min) 1607 ± 218
AUC glucose0–120 (mmol/l·min)1 667 ± 186
AUC insulin0–120 (nmol/l·min) 30 ± 12
AUC insulin0–120 (nmol/l·min)1 18 ± 8
ISI0,120 (mg·l2/mmol·mU·min) 40 ± 9
HOMA2 %B 65 ± 34
HOMA2 %S 59 ± 27
HOMA2 IR 2.0 ± 0.8
  1. 1stimulated secretion, area under curve at OGTT with value at 0 minutes as baseline.